Clinic
Northern Arizona Orthopaedics, LTD.
Northern Arizona Orthopaedics, LTD. was paid $2.14M by Medicaid between Jan 2018 and Apr 2022, across 37 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 38% of everything it billed.
33Billing provider infoNORTHERN ARIZONA ORTHOPAEDICS, LTD.
FLAGSTAFF, AZ 86001
FLAGSTAFF, AZ 86001
33aNPI1164495503assigned 02/08/2006
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$2.14M
24GClaims37,269
24DCodes billed37
24AFirst – last monthJan 2018 – Apr 2022
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Arizona
Rank by total paid#27 of 76
Median peer was paid$899K
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,944 | $503K | |
| 2019 | 9,780 | $530K | |
| 2020 | 7,107 | $411K | |
| 2021 | 7,706 | $501K | |
| 2022 | 2,732 | $194K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 38% | 16,506 | 15,532 | $819K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 4,213 | 4,002 | $320K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 12% | 3,227 | 3,157 | $261K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.7% | 1,275 | 1,226 | $144K |
| 95886 | 5.3% | 1,106 | 1,076 | $114K | |
| 64483 | 4.1% | 811 | 798 | $88K | |
| 20610 | 3.6% | 1,710 | 1,536 | $78K | |
| 95910 | 3.1% | 359 | 348 | $66K | |
| 72110 | 1.7% | 885 | 864 | $36K | |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 1.5% | 40 | 38 | $32K |
| 64493 | 1.2% | 242 | 228 | $25K | |
| 73564 | 1.1% | 717 | 642 | $24K |
25 more codes
| 73610 | <1% | 617 | $20K | |
| 73030 | <1% | 783 | $19K | |
| 73630 | <1% | 517 | $16K | |
| 73562 | <1% | 456 | $11K | |
| 99152 | <1% | 748 | $10K | |
| 29848 | <1% | 12 | $9K | |
| 73110 | <1% | 263 | $8K | |
| 73100 | <1% | 276 | $6K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,116 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 200 | $5K |
| 73502 | <1% | 122 | $4K | |
| 72100 | <1% | 132 | $4K | |
| 64494 | <1% | 62 | $3K | |
| 73140 | <1% | 92 | $2K | |
| 73130 | <1% | 85 | $2K | |
| 95909 | <1% | 12 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 190 | $1K |
| 64636 | <1% | 12 | $1K | |
| 73501 | <1% | 49 | $960.82 | |
| 72050 | <1% | 28 | $809.17 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 136 | $590.59 |
| 73560 | <1% | 16 | $347.15 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 176 | $267.25 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $133.45 |
| A4550 | Surgical trays | 0% | 66 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMUELLER, VERONICA (DIRECTOR OF REVENUE & REIMBURSEMENT)